Notice of Special Interest (NOSI): Secondary Analysis of Existing Datasets for Advancing Immune-mediated and Infectious Disease Research

First Application Due Date: June 16, 2021. Expires: May 8, 2024. This Notice of Special Interest (NOSI) is to support projects that use data, alone or in combination, to address scientific questions and knowledge gaps in basic or clinical research in immune-mediated and infectious diseases. Must submit to: PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

Supporting, Mobilizing, and Accelerating Research for TB Elimination (SMART4TB)

Application Due Date: Pending The goals of this planned award are: 1) to stimulate the development and implementation of new tools and approaches to accelerate the prevention, detection and management of tuberculosis in adults and children and 2) strengthen local capacity to design, implement, disseminate and use findings from TB research. Anticipated Award Date: 9/30/2021

Tuberculosis Research Advancement Centers (P30 Clinical Trials Not Allowed), expires June 16, 2021

Application Due Date: June 15, 2021 The purpose of this Funding Opportunity Announcement (FOA) is to solicit meritorious applications for the Tuberculosis Research Advancement Centers (TRACs) program. The main goal of these centers is to provide administrative and shared research support to foster and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to New Investigators. TRACs will provide core facilities, services and mentoring opportunities to achieve the goals of the program.

Landmark TB Trial Identifies Shorter-Course Treatment Regimen

Results from Study 31/A5349 were presented today at the Union World Conference on Lung Health. This study was conducted internationally through the Tuberculosis Trials Consortium (TBTC) and the AIDS Clinical Trials Group (ACTG) with funding from the CDC and NIH. Vanderbilt University Medical Center/Nashville Metro Public Health is a participating TBTC site, though did not enroll patients into this trial. April Pettit, VUMC faculty member, was a member of the protocol team.From the CDC Press Release:

Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed), expires 02/23/2021

Application Due Date(s): February 22, 2021, All applications are due by 5:00 PM local time of applicant organization. To support research to better define the role of the granuloma, the hallmark structure of pulmonary tuberculosis (TB), in TB disease and disease outcomes. Improved understanding of the granuloma will provide a much-needed knowledge base for the development of improved therapeutic approaches. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-057.html